Anril SR is a sustained-release formulation intended to support the management of certain cardiovascular conditions. This therapy is used for the prophylaxis of chronic stable angina pectoris, which is a type of heart-related chest pain. Angina is typically associated with reduced blood flow to the heart muscle due to coronary artery disease.

Quick Facts

• Primary Use: Prophylaxis of chronic stable angina pectoris.
• Benefit: May contribute to the reduced frequency of anginal episodes.
• Therapeutic Role: Supports cardiovascular health by addressing symptom burden associated with the condition.

The use of Anril SR may help reduce the incidence of anginal symptoms, allowing individuals to maintain a degree of physical function and supporting an improved sense of well-being. A healthcare provider can offer comprehensive guidance on the appropriate use of this medication and discuss potential benefits and risks. For detailed medical guidance on this type of condition, healthcare professional consultation is recommended.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Anril SR? — Official Regulatory Information

Anril SR (sustained-release Nitroglycerin) eligibility is defined by absolute prohibitions and restrictions outlined in regulatory labeling.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for individuals with certain co-medications or high-risk acute conditions:

• Co-Medication: Individuals taking Phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat) due to the risk of severe, life-threatening hypotension.
• Conditions: Patients with severe anemia, increased intracranial pressure (e.g., cerebral hemorrhage), acute circulatory failure or shock, or known hypersensitivity to nitrates.

---

Eligibility Restrictions and Special Populations

Population Category	Regulatory Status
Pediatric Patients	Safety and effectiveness have not been established (use is not recommended).
Older Adults	Use with caution due to increased risk of adverse effects like hypotension.
Pregnancy/Lactation	Use is not recommended unless considered essential by the physician, as safety data are inadequate.
Volume Depletion/Hypotension	Use with caution; may exacerbate existing low blood pressure.

Eligibility is limited to adults for the prophylaxis of chronic stable angina.

The official regulatory interaction profile for Anril SR (nitroglycerin) primarily focuses on pharmacodynamic reinforcement and formal co-administration restrictions documented in government labeling.

Contraindicated Combinations

The most critical restriction is the absolute contraindication with specific classes of medicinal products. Co-administration with Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is strictly prohibited across regulatory labels. This prohibition is due to the documented potential for severe, profound hypotension and syncope. Regulatory guidance also mandates specific time separation intervals (typically 24 to 48 hours, depending on the agent) before the use of organic nitrates following PDE-5 inhibitor administration.

Pharmacodynamic and Pharmacokinetic Interactions

Anril SR exhibits documented pharmacodynamic interactions with several categories of agents that share the effect of lowering blood pressure. Co-administration with other antihypertensive drugs or vasodilators carries a formal risk of additive hypotensive effects. The consumption of alcohol (ethanol) is also noted in official documentation to contribute to this additive vasodilating effect, which increases the risk of hypotension.

In terms of pharmacokinetic effects, regulatory labels document that nitroglycerin co-administration decreases the first-pass metabolism of certain drugs, such as oral Dihydroergotamine, which subsequently increases its exposure. Additionally, the co-administration of intravenous nitroglycerin is associated with a reduction in the anticoagulant effect of Heparin.

How Anril SR Works

Anril SR (Nitroglycerin) operates through the Nitric Oxide ( NO) signaling pathway, targeting regulatory enzymes within vascular smooth muscle to cause vasorelaxation. The core mechanism is defined by three interrelated biological domains: pro-drug activation, an intracellular signaling cascade, and the resulting systemic change in blood flow dynamics.

---

Pro-Drug Activation and Enzyme Targeting

Nitroglycerin functions as an inactive pro-drug. It undergoes biotransformation within vascular cells, often requiring thiol groups, to release the active chemical messenger, Nitric Oxide ( NO). The NO then specifically binds to and activates Soluble Guanylate Cyclase ( sGC), the pivotal enzyme that initiates the subsequent relaxing sequence.

---

The cGMP Cascade and Smooth Muscle Relaxation

Following sGC activation, the intracellular concentration of the second messenger cyclic Guanosine Monophosphate ( cGMP) rises. This cGMP surge leads to the activation of specific kinases that cause dephosphorylation of Myosin Light Chain, reducing the cell's ability to contract. This mechanistic cascade directly results in the relaxation of vascular smooth muscle and the widening of blood vessels (vasodilation) throughout the body.

---

Systemic Vasodilation and Decreased Cardiac Preload

The primary physiological consequence of this smooth muscle relaxation is venodilation (widening of the veins), which increases venous capacity. This reduces the volume of blood returning to the heart, thereby lowering pressure within the cardiac ventricles and decreasing cardiac preload. This physiological change—reduction in cardiac preload—is the key systemic consequence of the drug’s mechanism.

How to Use Anril SR

Anril SR (Nitroglycerin extended-release) is administered as an oral capsule intended for the long-term prevention of chronic stable angina. The sustained-release formulation dictates that the medicine must be used in a specific way to maintain efficacy and avoid the development of drug tolerance, a common issue with continuous nitrate exposure.

Standard Administration Protocol

The primary procedural constraint for using this formulation is the requirement for a daily nitrate-free interval. The dosing schedule must incorporate a period of 10 to 12 hours each day during which the drug is not administered. This is achieved by planning the dosing to ensure the body's concentration of the active ingredient decreases significantly for part of the day, thereby preserving the anti-anginal effect.

Usage Constraint	Standard Requirement
Route & Form	Must be taken orally as an extended-release capsule.
Capsule Integrity	The capsule must be swallowed whole; it is forbidden to crush, chew, or divide the capsule.
Indication Timing	Designated for prophylaxis (prevention) only; not for use in aborting an acute anginal episode.

Dosage and Scheduling

The standard adult regimen typically involves starting with a dose between 2.5 mg and 6.5 mg taken three to four times daily during the active period. The maintenance dose may be adjusted, based on clinical assessment, to a maximum of 26 mg per dose within the active dosing window.

When discontinuing the use of Anril SR after long-term treatment, the dosage must be reduced gradually over several days. For older adults, dose selection must be cautious, with initiation recommended at the low end of the dosing range.

Research Evidence / Overview of Studies for Anril SR

Evidence for Use in Chronic Stable Angina Prophylaxis

Research exploring the effects of long-acting organic nitrates like Anril SR was evaluated in Randomized Controlled Trials (RCTs). These are controlled studies where adult patients with chronic stable angina pectoris are randomly assigned to receive either the medicine or a placebo. These studies are relevant in trials assessing short-term or episodic symptom patterns, as this condition is characterized by fluctuating manifestations.

In these trials, researchers examined the medicine's role in evaluating outcomes related to physical discomfort. The main study outcomes examined changes in the recorded frequency of anginal episodes and tracked the use of fast-acting sublingual rescue medication. Studies also measured exercise tolerance, which is the amount of time a patient could physically exert themselves before chest discomfort began.

---

Study Focus on Symptom Control and Physical Function

Studies conducted during periods of increased symptom activity have focused on outcomes related to physical discomfort and activity level. Research examined not only patient-reported outcomes but also objective measures monitoring physiological strain or stress. This included monitoring time to ST-segment depression, a specific physiological measure, during exertion.

Data show patterns related to the recorded physical function of the patients undergoing stress tests. However, some studies reported that the measured changes in exercise capacity were sometimes limited compared to the patient's capacity at the start of the study. These findings describe group patterns, not personal outcomes.

---

Long-Term Studies and Follow-up Duration

Clinical trials submitted for regulatory review focused on assessing initial effects and generally involved short-term follow-up durations. Research describing efficacy was typically derived from specific, defined time intervals, such as one or two-week treatment periods.

Long-term effects are not fully established because follow-up durations were limited in the primary controlled trials. There is limited information for long-term outcomes to fully characterize how the observed response is maintained during treatment extending over many months or years.

---

Key Research Limitations and Areas of Uncertainty

Research highlights what is known—and what is still uncertain. A major limitation consistently reported across research is the concern regarding the potential for the development of tolerance. This means that with continuous use, findings indicate a pattern where the medicine's effectiveness may diminish over time. This challenge was observed in some studies where the continuous use of the medicine was associated with the inclusion of an interval without medicine in the protocols that were evaluated.

Key Studies & References

1. Label: NITROGLYCERIN SLOCAPS- nitroglycerin sustained-release capsules capsule – DailyMed
2. Label: NITRO-TIME- nitroglycerin capsule (Extended-Release) – DailyMed

Common questions about Anril SR (FAQ)

Q: Does Anril SR interact with alcohol?

A: Official product information indicates that alcohol (ethanol) has documented additive effects with Anril SR, meaning both substances may contribute to lowering blood pressure. This additive vasodilating effect may increase the potential for symptoms related to lowered blood pressure, such as lightheadedness, which should be considered.

Q: What should I do if I miss a dose of Anril SR?

A: If a dose is missed, patient information generally advises taking it as soon as you realize. However, if it is nearly time for the next scheduled dose, the official advice is to skip the missed dose entirely and continue with the next regularly scheduled dose. The product label advises against doubling doses to compensate for a missed one.

Q: Can Anril SR be used to stop an acute angina attack?

A: No, this medication is not indicated for the treatment of an ongoing, acute attack of chest pain (angina). Anril SR is an extended-release capsule specifically developed for the long-term prevention (prophylaxis) of chronic stable angina, and it does not have the rapid onset of action required for immediate symptom relief.

Q: What is the difference between Anril SR and immediate-release nitroglycerin?

A: Anril SR is a sustained-release formulation intended for the daily prevention of angina symptoms, providing an effect that lasts up to 12 hours. In contrast, immediate-release nitroglycerin forms, such as sublingual tablets, are designed to dissolve rapidly under the tongue and have a fast onset of action to stop an angina attack already in progress.

Q: How long does it take for Anril SR to start working?

A: Studies and official product documents indicate that the anti-anginal activity typically begins about 1 hour after the Anril SR capsule is swallowed. Since it is an extended-release formula, the therapeutic effect is then designed to maintain the effect for an extended period, generally up to 12 hours.

Official Storage and Disposal Requirements

Regulatory instructions for Anril SR, which contains nitroglycerin sustained-release, define specific conditions necessary for product stability and safety.

Storage Requirement	Official Condition (According to Labeling)
Temperature	Controlled Room Temperature: between 15 C and 30 C (59 F and 86 F). Do not freeze.
Environment	Must be stored away from excessive heat, moisture, and direct light.
Container	Keep in the original container, tightly sealed.
Child Safety	Mandatory to store the medication out of the sight and reach of children.

Disposal of Unused Product

Unused or expired Anril SR should be disposed of via an authorized drug take-back program. If a take-back program is unavailable, official guidelines permit discarding the product in the household trash after mixing it with an undesirable substance (like coffee grounds or dirt) and placing the mixture in a sealed bag. The medicine must not be flushed down a toilet or poured down a drain.